Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer.
Takaaki KonishiMichimasa FujiogiNobuaki MichihataHiroyuki OhbeHiroki MatsuiKiyohide FushimiMasahiko TanabeYasuyuki SetoHideo YasunagaPublished in: Japanese journal of clinical oncology (2022)
In this first comparative cost-effectiveness analysis of adjuvant chemotherapy plus trastuzumab versus trastuzumab monotherapy in the elderly, the latter was found favorable for elderly patients with human epidermal growth factor 2-positive breast cancer.
Keyphrases
- growth factor
- epidermal growth factor receptor
- metastatic breast cancer
- positive breast cancer
- early breast cancer
- middle aged
- endothelial cells
- combination therapy
- tyrosine kinase
- open label
- community dwelling
- randomized controlled trial
- clinical trial
- induced pluripotent stem cells
- pluripotent stem cells
- study protocol